1. Scrip
  2. >>R&D
  3. >>Clinical Trials

One Down, Two To Go For Adcetris’ Expansion In Lymphoma

 
• By Jessica Merrill

Takeda/Seattle Genetics announced positive Phase III data from the ALCANZA trial evaluating the antibody drug-conjugate in patients with cutaneous T-cell lymphoma (CTCL). Phase III studies in other potentially larger lymphoma indications are ongoing.

Partners Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. are pushing aggressively to expand the antibody-drug conjugate Adcetris (brentuximab vedotin) in new lymphoma indications. The first of three ongoing Phase III trials has read out positively, but late-stage studies are continuing in what are expected to be the larger commercial opportunities.

The companies announced Aug. 1 that the Phase III ALCANZA trial, evaluating Adcetris in patients with CD30-expressing cutaneous T-cell lymphoma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

2025’s Biggest Launches – Half-Year Progress Report

 
• By Andrew McConaghie

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

More from R&D

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 
• By Dexter Jie Yan

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.